In the midst of shifting political headwinds and a tight funding market, many life sciences companies are considering their M&A exit. Potential acquirers (both strategic and private equity) have plenty of dry powder and are...more
7/17/2025
/ Acquisition Agreements ,
Collaboration ,
Confidential Information ,
Corporate Sales Transactions ,
Due Diligence ,
Intellectual Property Protection ,
IP License ,
Life Sciences ,
Merger Agreements ,
Private Equity ,
Valuation
The U.S. government is pushing to redomesticate the manufacturing of pharmaceutical, biotech, gene therapy, and medical device products, both to bolster U.S. manufacturing generally and to address continuing shortages of...more
5/5/2025
/ Bayh-Dole Act ,
Biologics ,
Federal Funding ,
Federal Grants ,
Government Agencies ,
Healthcare ,
Intellectual Property Protection ,
Life Sciences ,
Manufacturing Facilities ,
Medical Devices ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Supply Chain ,
Tariffs